CD38 and neoplasm: Furthermore, several emerging approaches also offer new perspectives for cancer treatment.[30–32] Notably, daratumumab induces internalization or downregulation of the CD38 antigen on tumor cells, leading to a false-negative result in flow cytometry.[33]